Skip to main content
Clinical Trials/NCT04417829
NCT04417829
Completed
Not Applicable

The Impact of Transcatheter Aortic Valve Implantation on Left Ventricular Structure, Function and Outcome in Patients With Aortic Stenosis

Haukeland University Hospital0 sites600 target enrollmentJanuary 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Aortic Stenosis
Sponsor
Haukeland University Hospital
Enrollment
600
Primary Endpoint
The impact of TAVI on left ventriclar mass and hypertrophy regression
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

A prospective study of 600 patients with severe aortic stenosis (AS) and symptoms who underwent TAVI at the Haukeland university hospital, Bergen, Norway.

Detailed Description

A prospective study of 600 patients with severe aortic stenosis (AS) and symptoms who underwent TAVI at the Haukeland university hospital, Bergen, Norway between January 2012 and July 2019. Demographics, clinical data including cardiovascular risk factors, arterial and echocardiographic parameters were prospectively collected. The data on all-cause mortality will be collected. Echocardiograms (immediate before TAVI, at discharge after TAVI and at 6-12 months follow-up) will be analyzed. The main scientific objectives are: To assess survival benefits of TAVI according to baseline risk profile. To determine the echocardiographic predictors of left ventricular mass regression and left ventricular function recovery. To evaluate global LV load (Zva=valvular-arterial impedance) following TAVI. To assess the impact of various types of blood pressure responses immediately after TAVI on clinical outcomes.

Registry
clinicaltrials.gov
Start Date
January 2012
End Date
July 2019
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Haukeland University Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Hemodynamically severe aortic stenosis and symptoms
  • A decision of TAVI by Heart team
  • Patients undergoing TAVI (transcatheter aortic valve implantation)
  • Life expectancy \> 1-2 years

Exclusion Criteria

  • Sever frailty
  • Severly reduced cognitive function
  • Multiple comorbid conditions
  • Technically not suited for TAVI

Outcomes

Primary Outcomes

The impact of TAVI on left ventriclar mass and hypertrophy regression

Time Frame: From January 2012 to follow-up echo (6-12 months following TAVI)

To assess whether removal of valve stenosis by TAVI leads to regression of left ventricular mass (grams).

The impact of TAVI on left ventricular function recovery

Time Frame: From January 2012 to to follow-up echo (6-12 months following TAVI)

To assess improvement in systolic function (increase in ejection fraction) following TAVI

The impact of TAVI on arterial load (systemic arterial stiffness and arterial compliance).

Time Frame: From January 2012 to to follow-up echo (6-12 months following TAVI)

To assess improvement in echocardiographic arterial stiffness and arterial compliance and global left ventricular load (Zva=valvular-arterial impedance) following TAVI.

The impact of TAVI on all-cause mortality

Time Frame: From January 2012 to Mai 2020 (date for assesment vital status) + prolonged follow-up (up to 10 years)

To assess the long-term survival benefits of TAVI

Similar Trials